Delving into the Latest Updates on Equillium AUS Pty Ltd. with Synapse

概览

关联

3

项与 Equillium AUS Pty Ltd. 相关的临床试验

NCT05589610 / Completed临床2期

An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.

开始日期2022-12-19

申办/合作机构

Equillium, Inc.

[+1]

ACTRN12622001449729 / Recruiting临床1期

A Randomized, Double-blind, Placebo-controlled Phase I Study to assess the safety and tolerability of Subcutaneous EQ102 Administered in a Single and Multiple Ascending Dose Schedule.

开始日期2022-09-30

申办/合作机构

Equillium AUS Pty Ltd.

NCT04007198 / Completed临床1期

A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Moderate-to-Severe Uncontrolled Asthma

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.

开始日期2019-06-20

申办/合作机构

Equillium, Inc.

[+2]

100 项与 Equillium AUS Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Equillium AUS Pty Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Equillium AUS Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Equillium AUS Pty Ltd. 相关的转化医学

登录后查看更多信息